Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China.
Department of Microbiology and Immunology, The University of Western Ontario, London, ON, Canada.
Front Immunol. 2020 Mar 10;11:361. doi: 10.3389/fimmu.2020.00361. eCollection 2020.
Acquired immune deficiency syndrome (AIDS), which is caused by HIV infection, is an epidemic disease that has killed millions of people in the last several decades. Although combination antiretroviral therapy (cART) has enabled tremendous progress in suppressing HIV replication, it fails to eliminate HIV latently infected cells, and infected individuals remain HIV positive for life. Lifelong antiretroviral therapy is required to maintain control of virus replication, which may result in significant problems, including long-term toxicity, high cost, and stigma. Therefore, novel therapeutic strategies are urgently needed to eliminate the viral reservoir in the host for HIV cure. In this review, we compare several potential strategies regarding HIV cure and focus on how we might utilize chimeric antigen receptor-modified T cells (CAR T) as a therapy to cure HIV infection.
获得性免疫缺陷综合征（AIDS）是由 HIV 感染引起的传染病，在过去几十年中已导致数百万人死亡。尽管联合抗逆转录病毒疗法（cART）在抑制 HIV 复制方面取得了巨大进展，但它无法消除潜伏感染的 HIV 细胞，受感染的个体仍将终生携带 HIV 呈阳性。为了控制病毒复制，需要终身接受抗逆转录病毒治疗，这可能会导致包括长期毒性、高成本和污名化在内的重大问题。因此，迫切需要新的治疗策略来消除宿主中的病毒储存库，从而实现 HIV 的治愈。在这篇综述中，我们比较了几种潜在的 HIV 治愈策略，并重点探讨了如何利用嵌合抗原受体修饰的 T 细胞（CAR T）作为一种治疗方法来治愈 HIV 感染。
